About us

AT A GLANCE

Galderma is the leading company solely dedicated to the body’s largest organ: the skin. We are strategically positioned in resilient, highly attractive and consumer-focused sub-segments of Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.

Our unique Integrated Dermatology Strategy capitalizes on our distinctive strengths and competitive advantage.

Through trust-based partnerships with healthcare professionals, we meet consumer and patient needs with superior, lasting outcomes. Together, we are shaping the future of dermatology.

KEY FACTS ABOUT GALDERMA

4.082 B USD

2023 net sales

4

manufacturing sites

300+

million units produced a year

 

6,500+

employees operate from 50 sites in 40 countries, with our headquarters in Switzerland

770+

clinical trials funded across 30+ countries since 2019

 

160+

major regulatory approvals since 2019

 

11,000+

training events via our Global Aesthetic Injector Network (GAIN) program in 2023

 

130,000+

Training participants per year* engaged via our Global Aesthetic Injector Network (GAIN) program in 2023

* Single training contact – one healthcare professional can attend more than one training

 

Flemming Ornskov-GALDERMA-9679(940x400).jpg

 

Find out about our leadership team

A timeline of our history

1981
Foundation of Galderma as a joint venture between L’Oréal and Nestlé

Following the invention of the first Cetaphil formulation in 1947

1984
Galderma discovers Adapalene

1986
First commercial operations

1995
Launch of Differin for acne treatment

2000
Opening of our production site in Baie d’Urfé, Canada

2001
Licensing agreement for Metvix (Skin cancer)

2004
Opening of our production site in Hortolândia, Brazil

2007
Launch of Differin 0.3%

2008
Launch of Epiduo

2009
Launch of Azzalure and Restylane Injector

 

 

2009
Acquisition of Sculptra

2011
Acquisition of Q-med, maker of Restylane

2014
Nestlé Skin Health is founded – Galderma becomes a wholly-owned subsidiary of Nestlé

2019
Galderma debuts as the world’s largest independent global dermatology company following acquisition by a consortium of institutional investors

2021
Acquisition of Alastin

2022
Divestment of Alchemee

2022
Launch of Alluzience

2023
Launch of FACE by Galderma™, a cutting-edge aesthetic visualization tool that simulates treatment results in real time

2024
The FDA accepts the Biologics License Applications for nemolizumabfor the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis and grants Priority Review for the treatment of prurigo nodularis